IBA’s management team will host team will host a conference call and webcast conducted in English to present the half year results, followed by a Q&A session. The conference call will be held on ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) ...

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 19, 2026 after market ...

The notes will be senior, unsecured obligations of Indivior and will accrue interest at a rate of 0.625% per annum, payable semi-annually in arrears on March 15 and September 15 of each year, ...

On November 13, 2025, the Company announced additional 52-week follow-up data from the RESOLVE trial in eosinophilic esophagitis (“EoE”) demonstrating consistent results after dosing with EP-104GI.

No published clinical trial appears to have evaluated GlycoPezil as a proprietary formula. If you've been researching blood sugar support supplements lately, GlycoPezil is likely one of the names ...

NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury ...

DigitalOptometrics (DO), the leading provider of tele-optometry and remote ophthalmic care solutions, today announced the next major evolution of its platform at Vision Expo East, further advancing ...

The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign ™ group of companies, which invest in and ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including ...

About Iridex Corporation Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable ...

Net revenue was $18.8 million, compared to $14.2 million for the year ended December 31, 2024, up 33% Net income was $1.2 million, compared with $74,000 in 2024 Adjusted EBITDA was $1.6 million, ...